Dynacure, a French Phase 1/2 biotech developing therapies for neuromuscular diseases, withdrew its plans for an initial public offering on Monday, following its postponement last week. It had filed to raise $100 million by offering 6.3 million shares at a price range of $15 to $1IPOs Feed

By

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.